Eli Lilly has a winning formula.
By the numbers: In Q1 2026, the pharma giant reported $19.8B in revenue, up 56% YoY, blowing past expectations while raising full-year guidance to $82B–$85B.
Blockbusters. GLP-1 demand is driving nearly all growth, with Mounjaro at $8.7B (+125% YoY) and Zepbound at $4.1B (+80% YoY), reshaping Lilly’s revenue mix in real time.
At scale. Global volume rose 65%, offsetting pricing pressure as access expands. At the same time, international revenue jumped 81%, with accelerating distribution across Europe, China, and Brazil opening out-of-pocket markets.
Roadmap. Extending its lead across formats and innovation, 20K consumers are already on Lilly’s oral GLP-1 pill Foundayo, while next-gen obesity drug retatrutide is advancing through trials.
Fueled by GLP-1 profits, it’s investing in AI-driven drug discovery, partnering with NVIDIA, Insilico Medicine, and Profluent to accelerate development.
Punchline: From a single breakthrough to a scalable platform, GLP-1s have redefined Lilly’s business, positioning the company at the center of a new metabolic category.
